I have been following APPI, which merged into ABBI from its former holding company. It is now in a much better position to dramatically grow. It has several new FDA drug approvals, lots of cash, and its falgship drug, Abrzatane (sp?) continues to be confirmed a powerful cancer tumor fight agent. This is actualy a new nano tech delivery system, and should be the basis for use with other drugs. The only down side (and maybe this is not a negative at all) is that most of the stock is owned by one person, and the stock float is relatiavely small. I am not an analyst, and would appreciate any input any of you might have. On the surface, this looks like a probably multi bagger, but would appreciate other opinions. Incidentally, since the technology behind Abraxane is basically a new delivery system for old drugs, the FDA approval process is relatively fast.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst